Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000935
Chunk: 45

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 45
---
 Date (any Commitment Shares that are issued in respect of the Initial Commitment Fee are herein referred
to as the “”). Upon any issuance of Commitment Shares, the Company shall deliver to the Depositary
a Depositary Instruction Letter (as defined herein) with respect to the issuance of such Commitment Shares. For the avoidance of doubt,
(i) no payment is due by the Investor for any Commitment Shares, if any, issued to it by the Company pursuant to the terms of this Agreement
to release the Company of its liability to pay the Commitment Fee, and (ii) any remaining amount of the Commitment Fee shall be payable
by the Company to the Investor in cash in immediately available funds to an account designated by the Investor upon the termination of
this Agreement (the Company shall have the right, at the Company’s discretion, to issue Commitment Shares to the Investor to release
the Company of its liability to pay such remaining amount).

| -23- |

(f) . The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate,
to perform reasonable due diligence on the Company during normal business hours upon three (3) Business Days’ prior written notice.
The Company and its officers and employees shall provide material information and reasonably cooperate with the Investor in connection
with any reasonable request by the Investor related to the Investor’s due diligence of the Company. Each party hereto agrees not
to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any
purpose other than in connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that
the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to
protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person
acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes material, non-public information
about the Company or its Subsidiaries, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated
by Regulation FD. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as determined
in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents,
if the Investor is holding any Securities at the time of the disclosure of material, non-public information, the Investor shall have the